| As of Thursday, August 13th: |
Since the start of the quarter, the Q2 growth rate has risen from -31.1% to -28%. (Data provided by Thomson Reuters)
LATEST EARNINGS RESULTS
- UK Ministers Mull Law to Curb Bank Bonuses: Report
- US Builds Crime Cases on Clients of UBS
- Hugo Chavez Bails Out Allen Stanford-Hit Island
- Apple Board to Discuss Schmidt Replacement: Report
- How Much Would You Pay for Chocolate? Not This Much
- Las Vegas Sands Clears Way for Asian IPO
- Hong Kong Snaps out of Recession with 3.3% Growth
- Homebuyers Scramble to Beat Tax Credit Deadline
- VW to Buy 42% Stake in Porsche
- GM to Face 'Extremely Difficult Time' Starting 2012: Economist
- Pros Say: Economy Needs 'Coddling' to Avoid a 'W-Shape'
- Forget Wal-Mart (Walmart?), What About JP Morgan Chase (& Co.?)
- How Many NFL Blackouts Will We Have This Season?
- Oil Should Be Priced at $50-55: Strategist
- Will Apple, RIM and Others Enjoy Happy Holidays?
- Wal-Mart Stores: Hyphenate Less
- Expect 'U-Shaped' Market Bottom: Strategist
- Forget Tech and Banks — Buy These Sectors Instead: Strategist
|
CNBC'S MOST SHARED
- How Many Soccer Players Does it Take to Put On a T-Shirt?
- Dollar Bulls May Gain Upper Hand: Forex Analyst
- Existing-Home Sales Rise, Helped by Lower Prices
- Cramer: Citigroup Is 'Red Hot'
- More Workers Are Increasing Retirement Savings: Fidelity
- Stocks Gain 1.3% After Fed's 'Rosy' Outlook
- Consumer Confidence Stronger in August: Survey
- Second Stimulus Needed to Avoid Lost Decade: Krugman
- Freddie Mac Posts First Profit in 2 Years; Shares Jump
- Housing Shows Stablization, Led By Strong Demand
Text Size 
Merck said second-quarter earnings fell, hurt by lower sales of its cholesterol drugs, but income from partnerships and a rebound in sales of asthma drug Singulair helped the drugmaker beat profit forecasts.
 |
CNBC.com Merck Earnings |
Merck [MRK
Loading...
()
], whose shares rose more than 4 percent on Tuesday, earned $1.59 billion, or 74 cents per share. That compares with $1.77 billion, or 82 cents per share, in the year-earlier period.
Merck, which plans to acquire Schering-Plough [SGP
Loading...
()
] in coming months, said it earned 83 cents per share, excluding special items. Analysts on average expected 77 cents, according to Reuters Estimates.
Revenue fell 3 percent to $5.90 billion but came in $70 million above the Reuters Estimate forecast. Sales would have risen 3 percent if not for the strong dollar, which undermines the value of overseas sales.
Sanford Bernstein analyst Tim Anderson said Merck's equity income of $587 million from joint ventures, including its cholesterol partnership with Schering-Plough, was 15 percent higher than his forecast and helped drive the earnings beat.
Results were helped by a 10 percent decline in marketing and administrative expenses. Moreover, the drugmaker's effective tax rate, excluding special charges and merger-related costs, was 20.4 percent, a benefit of about 5 percentage points due to favorable tax settlements.
A bright spot in the earnings report was Singulair, Merck's asthma drug whose sales have steadily declined in the past year due to safety concerns. Its quarterly sales jumped 16 percent to $1.3 billion.
Sales of Januvia, a relatively new diabetes treatment, rose 38 percent to $462 million.
But combined sales of cholesterol fighters Zetia and Vytorin, sold in partnership with Schering-Plough, fell 10 percent to $1 billion. The drugs have lost favor with many doctors following a pair of clinical trials that cast doubt on their effectiveness.
Results were also hampered by Gardasil, Merck's vaccine against the virus that causes cervical cancer. Gardasil sales fell 18 percent to $268 million — hurt by rival vaccine made by GlaxoSmithKline [GSK
Loading...
()
].
Merck stuck with its full-year 2009 profit forecast of $3.15 to $3.30 per share excluding special items, and its full-year revenue forecast of $23.2 billion to $23.7 billion.
The company expects its acquisition of Schering-Plough to close in the fourth quarter.
- Wal-Mart Profit Tops Street; Same-Store Sales Lower
The world's largest retailer reported earnings that beat analysts' forecasts by 3 cents a share, and the retailer's shares edged higher in pre-market trading.
- Kohl's Sees Weakness Ahead; Shares Fall
Kohl's issued a disappointing outlook for the rest of 2009 Thursday, citing higher costs from opening new stores and persistently frugal shoppers, and shares fell 1 percent.
- Monsanto Affirms Full-Year Profit Outlook
Monsanto, the world's biggest seed maker, reaffirms its full-year profit outlook at the low end of its previously announced guidance.
- Wal-Mart Profit Tops Street; Same-Store Sales Lower
- Dr Pepper Snapple Profit Tops View; Outlook Raised
Dr Pepper Snapple Group reported a much higher-than-expected quarterly profit Thursday and raised its full-year outlook, helped by easing packaging and ingredient costs.
- Dr Pepper Snapple Profit Tops View; Outlook Raised
- SingTel Profit Rises 10.3%, Below Consensus
- Australia's Telstra Sees Challenging Year Ahead
- Macy's Tops Profit Forecast, Disappoints on Outlook
- Sara Lee Posts $14 Million Loss in Fiscal Fourth Quarter
- Applied Materials Expects to Break Even This Quarter
- Dynegy to Sell Assets, Plans Job Cuts
- Hormel Foods To Boost its 2009 Profit Forecast
- Nortel's CEO to Step Down, Board of Directors to Shrink
- Berkshire Swings to Profit in Second Quarter
- AIG Posts First Profit in 7 Quarters
- Fannie Mae Asks for More Aid After Sharp Loss
- CBS Profit Beats Street View; Shares Jump
- Crocs Shares Catapult Higher on Earnings Report
- Cisco Earnings Fall but Beat Expectations
- News Corp May Charge for Web News, Blasts Amazon
Data is a real-time snapshot *Data is delayed at least 15 minutes